Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liver Isolated Oxaliplatin for colorectal cancer liver metastases
2025-523261-25-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Feb 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in colorectal cancer (CRC), sponsored by UZ Leuven. Primary endpoint: Incidence of adverse events. Planned start Feb 2026; status: authorised.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2025-523261-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523261-25-00.